Regenicin, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023
May 15, 2023 at 02:39 pm EDT
Share
Regenicin, Inc. reported earnings results for the second quarter and six months ended March 31, 2023. For the second quarter, the company reported net loss was USD 0.336435 million compared to USD 0.166649 million a year ago.
For the six months, net loss was USD 0.613949 million compared to USD 0.320774 million a year ago.
Regenicin, Inc. is a biotechnology company that is focused on the development of regenerative cell therapies to restore the health of damaged tissues and organs. The Company is focused on developing and commercializing a lifesaving technology through the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is a graftable cultured epithelium skin substitute containing both epidermal and dermal components. It is focused on developing its product, TempaDerm. TempaDerm cells develop banks of cryo-preserved (frozen) cells and cultured skin substitutes to provide a continuous supply of non-allogenic skin substitutes to treat smaller wound areas in patients, such as ulcers. Its application is used for the treatment of chronic skin wounds.
REGENICIN, INC. 
